|
WO2004099388A2
(en)
|
2003-03-05 |
2004-11-18 |
Proteologics, Inc. |
Cbl-b polypeptides, complexes and related methods
|
|
CN101365806B
(zh)
|
2005-12-01 |
2016-11-16 |
医学预后研究所 |
用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
|
|
ES2566502T3
(es)
|
2006-09-13 |
2016-04-13 |
The Trustees Of Columbia University In The City Of New York |
Agentes y métodos para provocar una respuesta inmune antitumoral
|
|
AT506041A1
(de)
|
2007-12-10 |
2009-05-15 |
Univ Innsbruck |
Verfahren zur erhöhung der immunreaktivität
|
|
CA2710462C
(en)
|
2008-02-05 |
2015-11-24 |
F. Hoffmann-La Roche Ag |
Pyridinones and pyridazinones
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
KR101862327B1
(ko)
|
2010-05-07 |
2018-05-29 |
질레드 코네티컷 인코포레이티드 |
피리돈 및 아자-피리돈 화합물 및 사용 방법
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
EP2471548A1
(de)
|
2010-12-28 |
2012-07-04 |
Apeiron Biologics AG |
siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
|
|
WO2013067264A1
(en)
|
2011-11-03 |
2013-05-10 |
Genentech, Inc. |
8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
CA2861066C
(en)
|
2012-01-12 |
2024-01-02 |
Yale University |
Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
|
|
KR20150054994A
(ko)
|
2012-09-13 |
2015-05-20 |
에프. 호프만-라 로슈 아게 |
브루톤 티로신 키나아제의 억제제
|
|
US10308707B2
(en)
|
2013-12-02 |
2019-06-04 |
Aaron Diamond Aids Research Center |
Bispecific HIV-1-neutralizing antibodies
|
|
AU2014360446A1
(en)
|
2013-12-05 |
2016-06-09 |
Pharmacyclics, Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
BR112017025986A2
(pt)
|
2015-06-02 |
2018-08-14 |
Pharmacyclics Llc |
inibidores de tirosina quinase de bruton.
|
|
EP3325475B1
(en)
|
2015-07-17 |
2020-03-18 |
Takeda Pharmaceutical Company Limited |
Oxadiazole derivatives useful as hdac inhibitors
|
|
MX2019004707A
(es)
|
2016-10-26 |
2019-08-12 |
Iovance Biotherapeutics Inc |
Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US10842878B2
(en)
|
2016-11-22 |
2020-11-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
|
JP2020514252A
(ja)
|
2016-12-08 |
2020-05-21 |
アイカーン スクール オブ メディスン アット マウント シナイ |
Ｃｄｋ４／６媒介性がんを治療するための組成物および方法
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
WO2019148005A1
(en)
|
2018-01-26 |
2019-08-01 |
Nurix Therapeutics, Inc. |
Inhibitors of cbl-b and methods of use thereof
|
|
EP3746426A4
(en)
|
2018-01-29 |
2021-12-29 |
Dana Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
KR20210040355A
(ko)
*
|
2018-06-19 |
2021-04-13 |
바이오엔테크 유에스 인크. |
네오항원 및 이의 용도
|
|
JP7600123B2
(ja)
*
|
2018-10-15 |
2024-12-16 |
ニューリックス セラピューティクス，インコーポレイテッド |
ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
|
|
WO2020167518A1
(en)
|
2019-02-13 |
2020-08-20 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
EP3953346A1
(en)
|
2019-04-09 |
2022-02-16 |
Nurix Therapeutics, Inc. |
3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
|
|
EP3969447A1
(en)
|
2019-05-17 |
2022-03-23 |
Nurix Therapeutics, Inc. |
Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
|
|
MX2021015675A
(es)
|
2019-06-26 |
2022-02-03 |
Nurix Therapeutics Inc |
Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
|
|
WO2021021761A1
(en)
|
2019-07-30 |
2021-02-04 |
Nurix Therapeutics, Inc. |
Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
|
|
EP4034141A1
(en)
|
2019-09-24 |
2022-08-03 |
Nurix Therapeutics, Inc. |
Cbl inhibitors and compositions for expansion of immune cells
|
|
US20230024442A1
(en)
|
2019-11-08 |
2023-01-26 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for grading btk via ubiquitin proteosome pathway
|
|
US11820781B2
(en)
*
|
2019-12-04 |
2023-11-21 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
|
|
IL309796A
(en)
|
2021-07-14 |
2024-02-01 |
Nurix Therapeutics Inc |
Bifunctional compounds for BTK degradation with reduced IMID activity
|
|
WO2023004163A1
(en)
*
|
2021-07-23 |
2023-01-26 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk with enhanced imid activity
|
|
AU2022379494A1
(en)
|
2021-10-26 |
2024-05-30 |
Nurix Therapeutics, Inc. |
Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
|